To obtain more accurate biomarkers for AD, the field has turned to combining tau and Aß measures and calculating the ratio of tau to Aß42 in the CSF as a measure of AD pathology (Chiaravalloti et al., 2018; Fagan et al., 2007). This evidence concerns the gene MAPT and Alzheimer disease.